Response to Letter to the Editor Entitled: Concerning the Article by Arezoo Maleki-Hajiagha et al. Entitled Serum Prostate-Specific Antigen Level in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

Dear Editor,

We thank Kunicki et al. [1] for their interest in our paper [2] and for taking the time to give relevant and important comments regarding the inclusion of hirsutism or hyperandrogenism cases in our study. We agree with Kunicki et al. that the title is not appropriate, and it was better if the title of the article was: Serum Prostate-Specific Antigen Level in Women with Polycystic Ovary Syndrome and Hyperandrogenism: A Systematic Review and Meta-Analysis. Also, we should make some minor editing in the manuscript text.

• References

• 1 Kunicki M, Rudnicka E, Smolarczyk R. Concerning the article by Arezoo Maleki-Hajiagha et al. entitled: serum prostate-specific antigen level in women with polycystic ovary syndrome: a systematic review and meta-analysis. Horm Metab Res 2020; 52-251
• 2 Maleki-Hajiagha A, Razavi M, Rezaeinejad M. et al. Serum prostate-specific antigen level in women with polycystic ovary syndrome: a systematic review and meta-analysis. Horm Metab Res 2019; 51: 230-242
• 3 Melegos DN, Yu H, Ashok M. et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997; 82: 777-780
• 4 Azziz R, Carmina E, Dewailly D. et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
• 5 Johnson T, Kaplan L, Ouyang P. et al. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report Bethesda, NIH 2012; 1: 1-14
• 6 Eshre TR. Group A-SPCW Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25